Market capitalization | $2.11b |
Enterprise Value | $1.67b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 242.09 |
P/S ratio (TTM) P/S ratio | 304.85 |
P/B ratio (TTM) P/B ratio | 4.22 |
Revenue (TTM) Revenue | $6.91m |
EBIT (operating result TTM) EBIT | $-162.46m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
8 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:
8 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:
Sep '24 |
+/-
%
|
||
Revenue | 6.91 6.91 |
-
|
|
Gross Profit | 5.95 5.95 |
1,092%
1,092%
|
|
EBITDA | -162 -162 |
9%
9%
|
EBIT (Operating Income) EBIT | -162 -162 |
9%
9%
|
Net Profit | -162 -162 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company was founded on October 26, 2020 and is headquartered in Cambridge, the United Kingdom.
Head office | United Kingdom |
CEO | Saurabh Saha |
Employees | 76 |
Founded | 2013 |
Website | centessa.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.